%0 Journal Article
%A Caballero-Marcos, Aranzazu
%A Salcedo, Magdalena
%A Alonso-Fernandez, Roberto
%A Rodriguez-Peralvarez, Manuel
%A Olmedo, Maria
%A Graus Morales, Javier
%A Cuervas-Mons, Valentin
%A Cachero, Alba
%A Loinaz-Segurola, Carmelo
%A Iñarrairaegui, Mercedes
%A Castells, Lluis
%A Pascual, Sonia
%A Vinaixa-Aunes, Carmen
%A Gonzalez-Grande, Rocio
%A Otero, Alejandra
%A Tome, Santiago
%A Tejedor-Tejada, Javier
%A Alamo-Martinez, Jose Maria
%A Gonzalez-Dieguez, Luisa
%A Nogueras-Lopez, Flor
%A Blanco-Fernandez, Gerardo
%A Muñoz-Bartolo, Gema
%A Bustamante, Francisco Javier
%A Fabrega, Emilio
%A Romero-Cristobal, Mario
%A Martin-Mateos, Rosa
%A Del Rio-Izquierdo, Julia
%A Arias-Milla, Ana
%A Calatayud, Laura
%A Marcacuzco-Quinto, Alberto A
%A Fernandez-Alonso, Victor
%A Gomez-Gavara, Concepcion
%A Colmenero, Jordi
%A Muñoz, Patricia
%A Pons, Jose A
%T Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients.
%D 2021
%U http://hdl.handle.net/10668/17554
%X The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case-control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17–83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03–1.36), and therapy with renin–angiotensin–aldosterone system inhibitors (OR = 7.11, 95%CI: 1.47–34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline.
%K Clinical research/practice
%K Immune regulation
%K Immunosuppressant
%K Immunosuppression/immune modulation
%K Infection and infectious agents-viral
%K Infectious disease
%K Liver transplantation/hepatology
%~